Want to see GTBP full AI Analyst Report?
Top Page
GT Biopharma
(NASDAQ:GTBP)
Select Model
Select Model
Rating:43Neutral
Price Target:
$5.00
▲(1624.14% Upside)
Action:Reiterated
Date:10/22/26
GTBP scores low primarily due to weak financial performance (no revenue, sizable ongoing losses, and persistent cash burn with a thin/volatile equity base). Technicals add pressure as the stock trades below key moving averages with a negative MACD. Offsetting these negatives, recent corporate events slightly improve the outlook by reducing listing risk and improving financing flexibility, but they do not overcome the underlying pre-revenue cash-burn profile.
Positive Factors
Debt-Free Balance Sheet
The absence of debt limits interest expense and refinancing pressure while the company funds development of its oncology pipeline. Although liquidity remains constrained, a debt-free structure avoids creditor claims and preserves flexibility to direct future financing toward operations and clinical progress.
Negative Factors
Pre-Revenue Loss Profile
GT Biopharma has not yet established commercial revenue to offset research and operating costs, while losses remain substantial. This pre-revenue profile makes financial performance dependent on clinical progress and future financing, leaving limited evidence of a self-sustaining earnings model over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-Free Balance Sheet
The absence of debt limits interest expense and refinancing pressure while the company funds development of its oncology pipeline. Although liquidity remains constrained, a debt-free structure avoids creditor claims and preserves flexibility to direct future financing toward operations and clinical progress.
Read all positive factors
GT Biopharma (GTBP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$11.25M
Dividend YieldN/A
Average Volume (3M)79.27K
Price to Earnings (P/E)―
Beta (1Y)0.55
Revenue GrowthN/A
EPS Growth75.09%
CountryUS
Employees1
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-104.00
Shares Outstanding2,061,052
10 Day Avg. Volume61,010
30 Day Avg. Volume79,265
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.75
Price to Sales (P/S)0.00
P/FCF Ratio-0.34
Enterprise Value/Market Cap1.24
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.69
Forecast
1Y Price Target
$3.00Price Target Upside934.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-8.5
Revenue Forecast (FY)N/A
GT Biopharma Business Overview & Revenue Model
Company Description
GT Biopharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and bringing to market novel immuno-oncology treatments. Their innovative approach centers on a proprietary technology platform called Tr...
GT Biopharma Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -20.32M | -28.23M | -13.16M | 5.98M | -20.96M | -57.48M |
| Net Income | -22.08M | -28.35M | -13.16M | -7.60M | -20.88M | -58.01M |
Balance Sheet | ||||||
| Total Assets | 5.79M | 8.11M | 4.23M | 14.11M | 16.74M | 32.17M |
| Cash, Cash Equivalents and Short-Term Investments | 4.96M | 6.81M | 3.95M | 13.97M | 16.51M | 31.98M |
| Total Debt | 0.00 | 0.00 | 0.00 | 58.00K | 174.00K | 31.00K |
| Total Liabilities | 2.22M | 2.32M | 5.90M | 6.63M | 5.00M | 10.26M |
| Stockholders Equity | 3.57M | 5.79M | -1.67M | 7.48M | 11.73M | 21.91M |
Cash Flow | ||||||
| Free Cash Flow | -14.43M | -12.91M | -12.90M | -8.85M | -15.22M | -15.61M |
| Operating Cash Flow | -14.43M | -12.91M | -12.90M | -8.85M | -15.22M | -15.61M |
| Investing Cash Flow | 0.00 | 0.00 | 12.89M | -2.01M | 12.14M | -23.04M |
| Financing Cash Flow | 14.16M | 15.78M | 2.98M | 6.27M | -224.00K | 42.32M |
GT Biopharma Technical Analysis
Negative
0.29
Price Trends
6.93
Negative
8.40
Negative
10.04
Negative
Market Momentum
-0.31
Positive
40.73
Neutral
7.83
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GTBP, the sentiment is Negative. The current price of 0.29 is below the 20-day moving average (MA) of 6.41, below the 50-day MA of 6.93, and below the 200-day MA of 10.04, indicating a bearish trend. The MACD of -0.31 indicates Positive momentum. The RSI at 40.73 is Neutral, neither overbought nor oversold. The STOCH value of 7.83 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GTBP.
GT Biopharma Risk Analysis
GT Biopharma disclosed 60 risk factors in its most recent earnings report. GT Biopharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
GT Biopharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $8.99M | -0.29 | -93.49% | ― | ― | 94.38% | |
44 Neutral | $3.87M | -0.18 | -166.67% | ― | ― | 88.77% | |
43 Neutral | $11.25M | -0.05 | -443.08% | ― | ― | 75.09% | |
42 Neutral | $2.16M | -0.08 | -100.19% | ― | ― | 95.51% | |
42 Neutral | $4.33M | -0.06 | -205.45% | ― | ― | 78.16% |
* Healthcare Sector Average
GTBP
GT Biopharma
5.46
-11.90
-68.55%
TOVX
Theriva Biologics
0.20
-0.13
-40.06%
REVB
Revelation Biosciences
3.79
-32.33
-89.51%
DRMA
Dermata Therapeutics
0.78
-3.29
-80.81%
CERO
CERo Therapeutics Holdings
0.01
-1.87
-99.47%
AZTR
Azitra Inc
0.07
-0.48
-87.00%
GT Biopharma Corporate Events
Delistings and Listing ChangesRegulatory Filings and Compliance
GT Biopharma Regains Nasdaq Minimum Bid Compliance
Positive
Sep 25, 2026
GT Biopharma, Inc., a Nasdaq-listed biotech company, had fallen out of compliance with the exchange’s $1.00 minimum bid price requirement after its stock closed below that threshold for 30 consecutive business days as of November 20, 2025. I...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
GT Biopharma Expands Series M Preferred Financing Agreement
Positive
Sep 21, 2026
On September 14, 2026, GT Biopharma, Inc. entered into a securities purchase agreement for a private placement of Series M 10% Convertible Preferred Stock and associated warrants, initially covering up to 8,277.778 preferred shares with a stated v...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
GT Biopharma Restructures Capital via Series M Financing
Positive
Sep 15, 2026
On September 14, 2026, GT Biopharma entered into a private Securities Purchase Agreement for an offering of Series M 10% Convertible Preferred Stock and related warrants with an aggregate stated value of about $8.28 million and purchase price of $...
Business Operations and StrategyRegulatory Filings and ComplianceStock Split
GT Biopharma Implements Reverse Stock Split, Streamlines Capital Structure
Neutral
Sep 3, 2026
On September 2, 2026, GT Biopharma eliminated eleven previously designated but unused series of preferred stock from its charter after confirming that no shares of those series were outstanding, including the full conversion of all Series C prefer...
Business Operations and StrategyShareholder MeetingsStock Split
GT Biopharma Shareholders Approve Reverse Split and Incentive Plan
Positive
Aug 14, 2026
On August 14, 2026, GT Biopharma, Inc. held its Annual Meeting of Stockholders, with approximately 52.68% of eligible shares represented, and shareholders elected four directors and ratified Weinberg Company, P.A. as independent accountants for t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.